These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related]
6. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417 [TBL] [Abstract][Full Text] [Related]
7. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis. Isaacson SH; Coate B; Norton J; Stankovic S J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320 [TBL] [Abstract][Full Text] [Related]
8. The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study. Evidente VGH; DeKarske D; Coate B; Abler V Ther Adv Neurol Disord; 2024; 17():17562864241228350. PubMed ID: 38476466 [TBL] [Abstract][Full Text] [Related]
9. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators. Yasue I; Matsunaga S; Kishi T; Fujita K; Iwata N J Alzheimers Dis; 2016; 50(3):733-40. PubMed ID: 26757194 [TBL] [Abstract][Full Text] [Related]
12. An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression. DeKarske D; Alva G; Aldred JL; Coate B; Cantillon M; Jacobi L; Nunez R; Norton JC; Abler V J Parkinsons Dis; 2020; 10(4):1751-1761. PubMed ID: 32804101 [TBL] [Abstract][Full Text] [Related]
13. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. Ballard C; Youakim JM; Coate B; Stankovic S J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083 [TBL] [Abstract][Full Text] [Related]
14. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Espay AJ; Guskey MT; Norton JC; Coate B; Vizcarra JA; Ballard C; Factor SA; Friedman JH; Lang AE; Larsen NJ; Andersson C; Fredericks D; Weintraub D Mov Disord; 2018 Nov; 33(11):1769-1776. PubMed ID: 30387904 [TBL] [Abstract][Full Text] [Related]
15. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis. Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817 [TBL] [Abstract][Full Text] [Related]
16. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643 [TBL] [Abstract][Full Text] [Related]
17. Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study. Alva G; Cubała WJ; Berrio A; Coate B; Abler V; Pathak S J Alzheimers Dis; 2024; 98(1):265-274. PubMed ID: 38427485 [TBL] [Abstract][Full Text] [Related]